QimerBio Therapeutics

QimerBio Therapeutics is a biotech company, spin-off of Cima, the University Clinic of the University of Navarra and the University of Navarra. 

The main objective is the discovery and development of adoptive cell therapies, from proof-of-concept to clinical value stages, focusing on meeting unmet medical needs in the treatment of cancer and autoimmune diseases.

Formed in July 2024, the company presents an approach that integrates cutting-edge technology to develop innovative CAR-Ts that bring a novel solution to the treatment of both hematological and other types of tumors.

QimerBio is formed by a team of professionals of national and international reference in the development of immunotherapies with CAR-T cells and their application to the field of hematology, with extensive experience in immunotherapy research studies, as well as in the development of clinical trials that have led to the approval of existing drugs.

QT014 represents a novel non-viral CAR-T cell therapy designed to address the current limitations (efficacy, toxicity and cost) of approved CAR-T therapies targeting BCMA and in clinical development.

QT014 represents a novel non-viral CAR-T cell therapy designed to address the current limitations (efficacy, toxicity and cost) of approved CAR-T therapies targeting BCMA and in clinical development.

QuimerBio seeks to change the treatment of multiple myeloma with an innovative solution, bringing new hope to patients suffering from this disease. To this end, the team is working on the development of several technological platforms that respond to the needs of current treatments.